Cite

    Mavratzas, A., Baek, S., Gerber, B., Schmidt, M., Moebus, V., Foerster, F., Grischke, E., Fasching, P., Strumberg, D., Solomayer, E., Klare, P., Windemuth-Kieselbach, C., Hartmann, S., Schneeweiss, A., & Marmé, F. (2019). sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. Breast, 45, 22–28. http://access.bl.uk/ark:/81055/vdc_100082065662.0x000029